Lung Neoplasms Clinical Trial
Official title:
Audio Technology To Detect Lung Cancer Earlier
A cross-sectional study of prospectively collected cough audio recordings using spectral analysis.
In the UK lung cancer is the leading cause of cancer death, also, UK survival rates are
poorer compared to other European countries. Lung cancer is plagued by late presentation; 70%
present with advanced incurable disease and a third die within 90 days of diagnosis. As such,
there is a clear and urgent need to achieve earlier diagnosis of lung cancer. Symptomatic
presentation is the most common route to lung cancer diagnosis and symptoms may be present
for many months before diagnosis, even in early stage disease. The most common (68%)
presenting symptom is cough. Unfortunately cough is also common with other illnesses.
Furthermore, a high proportion of those at high-risk of lung cancer have pre-existing cough
or respiratory disease (e.g. ex- or current- smokers, patients with chronic obstructive
pulmonary disease (COPD)). Cough sounds are known to vary according to underlying lung
pathology and could therefore have diagnostic value. Potentially, there may be unique cough
and/or respiratory sounds or patterns associated with lung cancer that are not detectable by
the human audio spectrum. Identification of a tool that accurately discriminates lung cancer
cough could be pivotal.
This is a prospective cross-sectional study that will involve subjective analysis of
spectrograms of cough recorded from individuals with "normal" lungs, individuals at high-risk
for lung cancer (COPD and other chronic lung diseases) and individuals with lung cancer. 24
hour ambulatory audio recordings will be prospectively collected from patients attending
respiratory medicine clinics at Queen Elizabeth University Hospital (QEUH), Glasgow.
Participants will be given a free-field lapel microphone and mp3 recorder for 24h. The
Leicester Cough Monitor (LCM) will be used to extract the cough sounds from the 24h
recordings. The LCM is an automated cough detection system that was developed by Dr Surinder
Birring (Kings College Hospital). It uses an algorithm to automatically identify cough sounds
from audio recordings, which is then able to provide data on cough frequency. As part of this
process, the LCM splices out 1 second sound clips for all parts of the audio recordings that
are identified as being (i) a cough sound or (ii) a non-cough sound.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03357094 -
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
|
N/A | |
Recruiting |
NCT05543954 -
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
|
Early Phase 1 | |
Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
N/A | |
Completed |
NCT02531737 -
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
|
Phase 2 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02284633 -
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
||
Completed |
NCT02106143 -
RejuvenAirâ„¢ System Lobectomy Safety and Histology Study
|
N/A | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Enrolling by invitation |
NCT01687647 -
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
|
Phase 3 | |
Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00351962 -
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
|
N/A | |
Terminated |
NCT00356525 -
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
|
Phase 2 | |
Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT00090701 -
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|